BioCryst Pharmaceuticals
BCRX

$7.85

4.24%

Market Cap: 1.62B

About: BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Employees: 531

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 4 analysts

0

News positive %

of 6 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

20% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 70

0.47% more ownership

Funds ownership: 86.34% [Q4 2023] → 86.81% (+0.47%) [Q1 2024]

0% more funds holding

Funds holding: 234 [Q4 2023] → 234 (+0) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 5 [Q4 2023] → 5 (+0) [Q1 2024]

0% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 30

14% less capital invested

Capital invested by funds: $1.06B [Q4 2023] → $910M (-$150M) [Q1 2024]

16% less call options, than puts

Call options by funds: $7.81M | Put options by funds: $9.31M

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$12

53%

upside

Avg. target

$17.25

120%

upside

High target

$30

282%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

JMP Securities Jonathan Wolleben	91%upside $15	Market Outperform Maintained	7 May 2024
HC Wainwright & Co. Andrew Fein	282%upside $30	Buy Reiterated	7 May 2024
Needham Serge Belanger	53%upside $12	Buy Reiterated	7 May 2024
Needham Serge Belanger	53%upside $12	Buy Reiterated	10 Apr 2024

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about BCRX published over the past 30 days

BioCryst to Report Second Quarter 2024 Financial Results on August 5

RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2024 financial results on Monday, August 5, 2024.

BioCryst to Report Second Quarter 2024 Financial Results on August 5

Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects

BioCryst Pharmaceuticals develops complement-mediated and rare disease treatments using a structure-guided drug design process. The company's pipeline also includes promising drug candidates in pivotal phases and pre-clinical stages. The company relies heavily on Orladeyo, which represents 95.8% of its total revenues.

Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects

Zacks Investment Research

BioCryst (BCRX) Upgraded to Strong Buy: Here's Why

BioCryst (BCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

BioCryst (BCRX) Upgraded to Strong Buy: Here's Why

Zacks Investment Research

Wall Street Analysts See a 92.57% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 92.6% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 92.57% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

ORLADEYO® (berotralstat) Approved in Peru

RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older.

ORLADEYO® (berotralstat) Approved in Peru

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., July 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted five newly-hired employees stock options to purchase an aggregate of 46,850 shares, and restricted stock units (RSUs) covering an aggregate of 19,435 shares, of BioCryst common stock. The options and RSUs were granted as of June 28, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., June 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 74,875 shares, and restricted stock units (RSUs) covering an aggregate of 39,050 shares, of BioCryst common stock. The options and RSUs were granted as of May 31, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment

Additional results from largest body of evidence on attenuated androgen use in HAE reinforce need for access to safer and more tolerable HAE prophylaxis options Additional results from largest body of evidence on attenuated androgen use in HAE reinforce need for access to safer and more tolerable HAE prophylaxis options

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment

BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology

RESEARCH TRIANGLE PARK, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) meeting in Valencia, Spain from May 31 to June 3, 2024.

BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology

ORLADEYO® (berotralstat) Approved in Mexico

RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Federal Commission for Protection against Health Risks (COFEPRIS) in Mexico has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older.

ORLADEYO® (berotralstat) Approved in Mexico

See News Rankings